Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Gynecological Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1504084

Survival Analysis of Recurrent Ovarian Cancer under Different PARP Inhibitor Treatment Patterns: A Single-Center Retrospective Study

Provisionally accepted
Jingtian Shen Jingtian Shen 1Xi Wang Xi Wang 2Mpano Olivier Mpano Olivier 1Ying Wang Ying Wang 1Yihan Shan Yihan Shan 1Xinning Lou Xinning Lou 1Piaopiao Ye Piaopiao Ye 1*Xiaojian Yan Xiaojian Yan 1*
  • 1 Department of Gynecology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • 2 Department of Obstetrics and Gynecology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, China

The final, formatted version of the article will be published soon.

    Objective To compare the effects of different treatment modes containing PARPis and traditional treatment modes on the survival of patients with recurrent ovarian cancer. Methods From December 2012 to December 2023, 131 recurrent ovarian cancer patients were screened. The patients were followed up retrospectively, and the relevant data was collected and analyzed. Results Eighty-three patients used PARPis throughout the treatment process, and the median OS was not reached. Forty-eight patients did not use PARPis, and the median OS was 45.4 months. The two groups ' BRCA gene status, NACT, postoperative residual disease status, and PFI differ (P < 0.05). There was no significant difference in recurrence characteristics between the PARPis use and non-use groups in first-line maintenance therapy (P < 0.05). The use of PARPis, CA125 level and PFI were the independent influencing factors of OS in patients with recurrent ovarian cancer (P < 0.05). The median OS of patients with PARPis maintenance treatment in the single-line, second-line and last-line has not been reached. The median OS in the multi-line group was 69.5 months. Conclusion The use of PARPis, CA125 level and PFI were independent influencing factors of OS in patients with recurrent ovarian cancer. The first-line maintenance use of PARPis will not cause differences in disease recurrence characteristics. Compared with the patients without PARPis, patients with recurrent ovarian cancer receiving PARPis maintenance therapy have longer OS. The group of patients with PARPis maintenance treatment in the second and last lines showed better OS (P < 0.05). However, OS was not significantly different between the second-line and last-line groups (P < 0.05). There was no significant difference in OS between the multiple-line use PARPis and single-line use PARPis groups.

    Keywords: ovarian cancer, PARP inhibitors, Retrospective study, Recurrence characteristics, survival analysis

    Received: 30 Sep 2024; Accepted: 18 Dec 2024.

    Copyright: © 2024 Shen, Wang, Olivier, Wang, Shan, Lou, Ye and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Piaopiao Ye, Department of Gynecology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
    Xiaojian Yan, Department of Gynecology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.